Carmen Burgaleta

Alcala De Henares, MD, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

PTCH1 is a reliable marker for predicting imatinib response in chronic myeloid leukemia patients in chronic phase.

PTCH1 is a reliable marker for predicting imatinib response in chronic myeloid leukemia patients in chronic phase.

Journal: PloS one

Published: March 08, 2017

Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea.

Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea.

Journal: Haematologica

Published: July 15, 2016

Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation.

Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation.

Journal: Haematologica

Published: March 23, 2016

Current opinion and consensus statement regarding the diagnosis, prognosis, and treatment of patients with essential thrombocythemia: a survey of the Spanish Group of Ph-negative Myeloproliferative Neoplasms (GEMFIN) using the Delphi method.

Current opinion and consensus statement regarding the diagnosis, prognosis, and treatment of patients with essential thrombocythemia: a survey of the Spanish Group of Ph-negative Myeloproliferative Neoplasms (GEMFIN) using the Delphi method.

Journal: Annals of hematology

Published: November 27, 2015

Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera.

Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera.

Journal: British journal of haematology

Published: September 10, 2015

Atypical IgM multiple myeloma with deletion of c-MAF.

Atypical IgM multiple myeloma with deletion of c-MAF.

Journal: International journal of laboratory hematology

Published: January 19, 2015

Adult-onset Diamond-Blackfan anemia with a novel mutation in the exon 5 of RPL11: too late and too rare.

Adult-onset Diamond-Blackfan anemia with a novel mutation in the exon 5 of RPL11: too late and too rare.

Journal: Clinical case reports

Published: September 01, 2014

Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months.

Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months.

Journal: Cancer medicine

Published: August 13, 2014

Do chronic myeloid leukemia patients with late "warning" responses benefit from "watch and wait" or switching therapy to a second generation tyrosine kinase inhibitor?

Do chronic myeloid leukemia patients with late "warning" responses benefit from "watch and wait" or switching therapy to a second generation tyrosine kinase inhibitor?

Journal: American journal of hematology

Published: July 16, 2014

Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea.

Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea.

Journal: Annals of hematology

Published: May 27, 2014

A team-based multidisciplinary approach to managing peripherally inserted central catheter complications in high-risk haematological patients: a prospective study.

A team-based multidisciplinary approach to managing peripherally inserted central catheter complications in high-risk haematological patients: a prospective study.

Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

Published: March 28, 2014

Pharmacological profiles of acute myeloid leukemia treatments in patient samples by automated flow cytometry: a bridge to individualized medicine.

Pharmacological profiles of acute myeloid leukemia treatments in patient samples by automated flow cytometry: a bridge to individualized medicine.

Journal: Clinical lymphoma, myeloma & leukemia

Published: September 02, 2013

Showing 1-12 of 15

Last Updated: 09/26/2026